No connection

Search Results

ABBV vs ALGS

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
ALGS
Aligos Therapeutics, Inc.
BEARISH
Price
$7.57
Market Cap
$46.6M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
ALGS
--
Forward P/E
ABBV
15.42
ALGS
-1.42
P/B Ratio
ABBV
-146.66
ALGS
0.87
P/S Ratio
ABBV
6.5
ALGS
21.31
EV/EBITDA
ABBV
15.27
ALGS
0.3

Profitability

Gross Margin
ABBV
71.46%
ALGS
0.0%
Operating Margin
ABBV
35.5%
ALGS
-12907.7%
Profit Margin
ABBV
4.0%
ALGS
0.0%
ROE
ABBV
137.96%
ALGS
-196.91%
ROA
ABBV
9.59%
ALGS
-69.33%

Growth

Revenue Growth
ABBV
9.1%
ALGS
-73.1%
Earnings Growth
ABBV
-88.7%
ALGS
--

Financial Health

Debt/Equity
ABBV
--
ALGS
0.1
Current Ratio
ABBV
0.72
ALGS
3.9
Quick Ratio
ABBV
0.47
ALGS
3.67

Dividends

Dividend Yield
ABBV
3.05%
ALGS
--
Payout Ratio
ABBV
490.15%
ALGS
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
ALGS BEARISH

ALGS exhibits severe financial distress, reflected in a Piotroski F-Score of 0/9 and a lack of Altman Z-Score, indicating extreme bankruptcy risk. The company reports massive negative profitability metrics, including a -12,907.69% operating margin and -196.91% ROE, alongside a 73.1% YoY revenue decline. Despite a strong analyst consensus of 'strong_buy' and a high target price of $80.25, the stock trades at a premium valuation (Price/Sales of 21.31) with no earnings or cash flow generation. Insider sentiment is neutral, and technical trends are bearish, underscoring a lack of market confidence. The combination of deteriorating fundamentals and speculative valuation creates a high-risk profile.

Strengths
Analyst consensus is strongly bullish with a $80.25 target price
Recent quarterly EPS growth shows strong momentum (+85.4% YoY, +37.2% Q/Q)
Positive earnings surprises in 2 of the last 4 quarters (average +3.87%)
Risks
Piotroski F-Score of 0/9 signals extreme financial distress and operational failure
Negative operating margin (-12,907.69%) and ROE (-196.91%) reflect deep unprofitability
73.1% YoY revenue decline indicates business contraction

Compare Another Pair

ABBV vs ALGS: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Aligos Therapeutics, Inc. (ALGS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile